Published in Clin Schizophr Relat Psychoses on June 17, 2013
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry (2015) 2.05
Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry (2015) 0.78
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Curr Treat Options Psychiatry (2017) 0.75
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
An SCN9A channelopathy causes congenital inability to experience pain. Nature (2006) 7.01
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 2.20
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry (2007) 2.13
Recurrent subthreshold depression in type 2 diabetes: an important risk factor for poor health outcomes. Diabetes Care (2013) 2.08
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol (2012) 1.97
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol (2008) 1.94
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol (2010) 1.93
Climate change effects on plague and tularemia in the United States. Vector Borne Zoonotic Dis (2007) 1.92
Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology (2002) 1.91
An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol (2007) 1.83
mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology (2009) 1.80
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol (2009) 1.76
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull (2009) 1.69
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol (2008) 1.68
Predicted exposures to steroid estrogens in U.K. rivers correlate with widespread sexual disruption in wild fish populations. Environ Health Perspect (2006) 1.67
Statistical modeling suggests that antiandrogens in effluents from wastewater treatment works contribute to widespread sexual disruption in fish living in English rivers. Environ Health Perspect (2009) 1.61
Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry (2004) 1.60
The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res (2005) 1.55
Retinal response to light in young nonaffected offspring at high genetic risk of neuropsychiatric brain disorders. Biol Psychiatry (2009) 1.53
First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role? Rheumatology (Oxford) (2009) 1.49
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry (2004) 1.49
Preserved awareness of their cognitive deficits in patients with schizophrenia: convergent validity of the SSTICS. Schizophr Res (2008) 1.48
Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage (2005) 1.47
A 4.0-T fMRI study of brain connectivity during word fluency in first-episode schizophrenia. Schizophr Res (2004) 1.46
Comparison of echocardiographic and cardiac magnetic resonance imaging measurements of functional single ventricular volumes, mass, and ejection fraction (from the Pediatric Heart Network Fontan Cross-Sectional Study). Am J Cardiol (2009) 1.45
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf (2012) 1.42
Conformance to evidence-based treatment recommendations in schizophrenia treatment services. Can J Psychiatry (2012) 1.41
Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull (2009) 1.40
The costs of early intervention in psychosis: restoring the balance. Aust N Z J Psychiatry (2012) 1.40
Panurethral stricture after photovaporization of the prostate for benign prostatic hyperplasia. J Endourol (2012) 1.37
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum (2007) 1.34
Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr Bull (2004) 1.31
Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem (2009) 1.29
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry (2007) 1.29
Using a Delphi process to develop an effective train-the-trainers program to train health and social care professionals throughout Europe. J Trauma Stress (2012) 1.21
Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum (2010) 1.21
Lack of extracellular superoxide dismutase (EC-SOD) in the microenvironment impacts radiation-induced changes in neurogenesis. Free Radic Biol Med (2007) 1.18
Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis (2012) 1.17
Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol (2005) 1.17
Priapism. J Sex Med (2004) 1.16
Do we see what we think we see? The complexities of morphological assessment. J Pathol (2009) 1.16
Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Schizophr Res (2005) 1.16
Public experiences of mass casualty decontamination. Biosecur Bioterror (2012) 1.15
Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med (2006) 1.15
Determinants of help-seeking and system related components of delay in the treatment of first-episode psychosis. Schizophr Res (2007) 1.14
A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat (2002) 1.13
Children and young people who are refugees, internally displaced persons or survivors or perpetrators of war, mass violence and terrorism. Curr Opin Psychiatry (2012) 1.13
Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett (2009) 1.13
Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Can J Psychiatry (2008) 1.09
Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg Med Chem Lett (2010) 1.09
Joint effect of depression and chronic conditions on disability: results from a population-based study. Psychosom Med (2007) 1.08
Fish oil vs olive oil for postoperative atrial fibrillation. JAMA (2013) 1.07
Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood (2013) 1.07
Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res (2011) 1.07
Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res (2004) 1.07
Schizophrenia and the motivation for smoking. Perspect Psychiatr Care (2002) 1.06
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry (2011) 1.06
Rate acceleration of the Baylis-Hillman reaction in polar solvents (water and formamide). Dominant role of hydrogen bonding, not hydrophobic effects, is implicated. J Org Chem (2002) 1.06
Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med (2005) 1.06
Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res (2008) 1.06
Questionnaires for 360-degree assessment of consultant psychiatrists: development and psychometric properties. Br J Psychiatry (2008) 1.05
One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res (2002) 1.05
Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res (2005) 1.04
Negative symptoms in first episode non-affective psychosis. Acta Psychiatr Scand (2002) 1.04
Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res (2004) 1.04
Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer (2007) 1.04
Peyronie's disease. J Sex Med (2004) 1.03
miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One (2013) 1.02
Probing the gluon self-interaction in light mesons. Phys Rev Lett (2009) 1.02
Variation in growth of infants with a single ventricle. J Pediatr (2012) 1.01
Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). Rheumatology (Oxford) (2010) 1.01
Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett (2008) 1.01
Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry (2007) 1.01
Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry (2011) 1.01
Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J Psychiatry Neurosci (2002) 1.01
CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn (2005) 1.00
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv (2002) 1.00
Predictors of quality of life in schizophrenia. Community Ment Health J (2005) 1.00
Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol (2009) 1.00
Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull (2007) 1.00
Benefits of enriched intervention compared with standard care for patients with recent-onset psychosis: a metaanalytic approach. Can J Psychiatry (2007) 0.99
Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett (2009) 0.99
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry (2014) 0.99
A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol (2010) 0.99
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res (2007) 0.98
Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res (2003) 0.98
Secondary stressors and extreme events and disasters: a systematic review of primary research from 2010-2011. PLoS Curr (2012) 0.97
Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry (2013) 0.97